Pradaxa Issues Explained

In October 2010, the U.S. Food and Drug Administration approved a prescription medication manufactured by Boehringer Ingelheim Pharmaceuticals under the brand name Pradaxa. (The chemical name for the medication is dabigatran etexilate mesylate.) Pradaxa is a blood thinner used specifically in patients who suffer from non-valvular atrial fibrillation, a condition in which the organ’s two …

Continue reading

Metal-on-Metal Implants Pose Unique Dangers for Patients

Debris from plastic components shed from hip implants into the bloodstream, causing bone loss and loosening the device. Metal-on-metal devices pose a different series of unique problems because metal debris is finer and greater in volume. This may cause a more response in hip replacement patients. This is due to how our bodies process the …

Continue reading

FDA Forces Hip Implant Manufacturers to Research Failures

Many metal-on-metal hip implant patients have experienced the frustrations associated with aggravating symptoms caused by the design of the hip replacement. One in particular went to see a specialist in Boston because nobody else could figure out why he was having problems. Many doctors would simply give shots for pain or tell patients not to …

Continue reading

FDA Receives Over 5,000 Reports of Hip Implant Problems

The unique threat of metal-on-metal implants is being discovered by researchers. All implants will release debris, but all-metal implants pose a particularly special problem because scavenger cells inside the body will convert the debris into biologically active metallic ions. This results in a reaction that may annihilate muscle and tissue. Doctors are attempting to pin-down …

Continue reading